A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.

Maria TrojanoLluís Ramió-TorrentàLuigi Me GrimaldiCatherine LubetzkiSven SchipplingKarleyton C EvansZheng RenKumar Kandadi MuralidharanStephanie LicataArie R Gafson

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)

Natalizumab 300 mg subcutaneous Q4W was comparable to 300 mg intravenous Q4W dosing with respect to efficacy, pharmacokinetics/pharmacodynamics, and safety.

Keyphrases

multiple sclerosis
white matter
high dose
low dose
systemic lupus erythematosus
disease activity